--- title: "BioCryst Pharmaceuticals (BCRX) news: lawsuit" url: "https://aibio.space/companies/biocryst-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BCRX lawsuit news. BioCryst Pharmaceuticals news for investors: BioCryst Pharmaceuticals sells Orladeyo, an oral daily pill that prevents attacks of…" --- Desk view · Opinion · Updated Oct 22, 2026 ## BioCryst is profitable now. The 2027 readout decides what comes next BioCryst has turned into a profitable one-drug company that is spending its Orladeyo cash on navenibart and outside deals rather than its own labs. The near-term story is U.S. Orladeyo growth and the pellet launch; the long-term story is whether navenibart works in phase 3 in 2027 and whether management buys good assets. Read the full desk view aibio.space Investor Rank · Opinion **6** /10 Neutral view Profitable on Orladeyo but dependent on that one drug, carrying $400 million of term debt and waiting until 2027 for navenibart phase 3 data. - **Technology**: 2/2 - **Odds**: 1/2 - **Balance sheet**: 1/2 - **Risk**: 1/2 - **Momentum**: 1/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Proven commercial drug.** Orladeyo is an approved oral kallikrein inhibitor with $158.2 million of Q2 sales; navenibart extends the same target to injections every three or six months. - **Odds**: **Navenibart is in phase 3.** Enrollment finished in June 2026 and top-line data are due in Q3 2027; rare disease phase 3 programs reach filing about 60% of the time. - **Balance sheet**: **Profitable but levered.** BioCryst held $354.0 million at June 30 and posted Q2 net income, while carrying $400 million of term debt due 2031. - **Main risk**: **Single-product dependence.** Orladeyo provides nearly all product revenue and faces a generic patent challenge and new HAE competitors. - **Watch next**: **Pellet launch numbers.** Q3 results on November 4 will be the first with pediatric pellet sales, and BCX17725 data are due by year end. ## Top news on BioCryst 1. 2026-08-05 Legal [BioCryst sues Annora, Hetero and Camber in Delaware over generic ORLADEYO](https://aibio.space/news/biocryst-sues-annora-hetero-camber-delaware-generic-orladeyo/) BioCryst filed the patent suit on March 10, 2025 after Paragraph IV notices from Annora Pharma. The 10-Q says the case is in early stages and no estimate of loss is possible. 2. 2026-06-29 Financings [BioCryst to close Birmingham discovery center, cuts 2026 spending outlook](https://aibio.space/news/biocryst-close-birmingham-discovery-center-cuts-2026-spending-outlook/) The HAE drugmaker will stop internal drug discovery and look outside for new programs. A later 8-K/A put severance at $6.2 million to $7.5 million, and a state WARN notice listed 47 jobs at the site. ## Dates **November 4, 2026** Third-quarter 2026 financial results [Source](https://www.biopharmawatch.com/news/BCRX/biocryst-reports-q3-2026-results-november-4) **By end of 2026** Proof-of-concept data from part 4 of the BCX17725 phase 1 trial in Netherton syndrome [Source](https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/exh_991.htm) **Q3 2027** Top-line ALPHA-ORBIT phase 3 results for navenibart, both 3- and 6-month doses [Source](https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/exh_991.htm) **By end of 2027** Planned U.S. regulatory filing for navenibart [Source](https://www.sec.gov/Archives/edgar/data/882796/000117184326002960/exh_991.htm) ## The money $354.0 million in cash, cash equivalents, restricted cash and investments at June 30, 2026, against $400 million of Blackstone term loans due January 2031. The 10-Q says resources are sufficient to fund operations for at least the next 12 months. [Source](https://www.sec.gov/Archives/edgar/data/882796/000162828026053300/bcrx-20260630.htm) Q2 2026 total revenue of $218.3 million, including Orladeyo net revenue of $158.2 million and $55.7 million recognized from the European navenibart license. [Source](https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/exh_991.htm) ## Risks on the record - Annora Pharma has filed to sell generic Orladeyo before four patents that expire in May 2040; BioCryst is suing in Delaware and the case is at an early stage. [Source](https://www.sec.gov/Archives/edgar/data/882796/000162828026053300/bcrx-20260630.htm) - BioCryst carries $400 million of floating-rate term loans from Blackstone, with interest at SOFR (1.75% floor) plus 4.50%. [Source](https://www.sec.gov/Archives/edgar/data/882796/000162828026053300/bcrx-20260630.htm) - Navenibart is unapproved, and BioCryst has ended internal discovery, so its pipeline beyond 2027 depends on navenibart, BCX17725 and future in-licensing. [Source](https://www.sec.gov/Archives/edgar/data/882796/000117184326004333/exh_991.htm) ## Questions investors ask ### What is aibio.space's Investor Rank for BioCryst Pharmaceuticals? 6 out of 10, our neutral view. Profitable on Orladeyo but dependent on that one drug, carrying $400 million of term debt and waiting until 2027 for navenibart phase 3 data. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### What does BioCryst Pharmaceuticals sell? BioCryst sells Orladeyo (berotralstat), an oral once-daily pill that prevents hereditary angioedema attacks, plus Rapivab for influenza. Orladeyo had net revenue of $158.2 million in the second quarter of 2026. [Source](https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/exh_991.htm) ### When will BioCryst report navenibart phase 3 results? BioCryst expects top-line ALPHA-ORBIT results for both the three-month and six-month doses in the third quarter of 2027. Enrollment finished in June 2026. [Source](https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/exh_991.htm) ### Who is the CEO of BioCryst? Charlie Gayer is president and chief executive officer of BioCryst. He was quoted in that role in the company's August 5, 2026 second-quarter results. [Source](https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/exh_991.htm) ### How much cash and debt does BioCryst have? BioCryst had $354.0 million in cash, cash equivalents, restricted cash and investments at June 30, 2026. It owed $400 million under a Blackstone term loan that matures in January 2031. [Source](https://www.sec.gov/Archives/edgar/data/882796/000162828026053300/bcrx-20260630.htm) ### Is there a generic challenge to Orladeyo? Yes. Annora Pharma filed an ANDA challenging four Orladeyo patents that expire in May 2040, and BioCryst sued Annora and Hetero in Delaware. Six other Orange Book patents expiring in 2035 are not challenged. [Source](https://www.sec.gov/Archives/edgar/data/882796/000162828026053300/bcrx-20260630.htm) ### What is the latest BioCryst Pharmaceuticals (BCRX) stock news? Our latest story on BioCryst Pharmaceuticals, dated Aug 5, 2026: "BioCryst sues Annora, Hetero and Camber in Delaware over generic ORLADEYO". BioCryst filed the patent suit on March 10, 2025 after Paragraph IV notices from Annora Pharma. The 10-Q says the case is in early stages and no estimate of loss is possible. [Source](https://aibio.space/news/biocryst-sues-annora-hetero-camber-delaware-generic-orladeyo/) ### What is BioCryst Pharmaceuticals's latest stock offering or financing news? Our latest financing story, dated Jun 29, 2026: "BioCryst to close Birmingham discovery center, cuts 2026 spending outlook". The HAE drugmaker will stop internal drug discovery and look outside for new programs. A later 8-K/A put severance at $6.2 million to $7.5 million, and a state WARN notice listed 47 jobs at the site. [Source](https://aibio.space/news/biocryst-close-birmingham-discovery-center-cuts-2026-spending-outlook/) ### Is BioCryst Pharmaceuticals facing a lawsuit? Our latest legal story, dated Aug 5, 2026: "BioCryst sues Annora, Hetero and Camber in Delaware over generic ORLADEYO". BioCryst filed the patent suit on March 10, 2025 after Paragraph IV notices from Annora Pharma. The 10-Q says the case is in early stages and no estimate of loss is possible. Claims in lawsuits are allegations until a court rules. [Source](https://aibio.space/news/biocryst-sues-annora-hetero-camber-delaware-generic-orladeyo/) ### What is BioCryst Pharmaceuticals's market cap? We do not publish live share prices. In its annual report, BioCryst Pharmaceuticals, Inc. put the market value of shares held by non-affiliates (public float) at $1.86 billion as of Jun 30, 2025. Source ### Is BioCryst Pharmaceuticals a smaller reporting company? SEC records list BioCryst Pharmaceuticals, Inc.'s filer category as: Large accelerated filer. Source ### Where is BioCryst Pharmaceuticals headquartered? SEC records list its business address as 4505 EMPEROR BOULEVARD, DURHAM, NC, 27703. Source ### When does BioCryst Pharmaceuticals's fiscal year end? BioCryst Pharmaceuticals, Inc.'s fiscal year ends on December 31, per SEC records. Source ### What did BioCryst Pharmaceuticals last file with the SEC? Its most recent filing in our record is a 10-Q filed 2026-08-05. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/882796/000162828026053300/bcrx-20260630.htm) ### What industry is BioCryst Pharmaceuticals in? Its SEC industry code (SIC 2836) is Biological Products, (No Diagnostic Substances). Source ## Legal and investor matters Checked against BioCryst Pharmaceuticals filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. 1. 2026-06-25 Other BioCryst to close discovery center and end internal discovery programs On 2026-06-25 the board of BioCryst Pharmaceuticals approved a plan to discontinue its internal discovery programs and close its Discovery Center of Excellence in Birmingham, Alabama. The company said implementation should be substantially complete by the end of 2026. It said it could not yet estimate the total cost of the plan and would file an amendment to its Form 8-K once it could. [BioCryst Form 8-K (Item 2.05)](https://www.sec.gov/Archives/edgar/data/882796/000117184326004333/f8k_062926.htm) 2. 2026-01-23 Financing BioCryst borrows $400 million under Blackstone term loan On 2026-01-23 BioCryst Pharmaceuticals entered into a loan agreement with Blackstone Alternative Credit Advisors and Blackstone Life Sciences Advisors, with Wilmington Trust as agent. The agreement provided initial term loans of $400 million, which were funded on the closing date. BioCryst disclosed the loan in the same Form 8-K that reported the completion of its Astria Therapeutics acquisition. [BioCryst Form 8-K (Items 1.01, 2.01, 2.03)](https://www.sec.gov/Archives/edgar/data/882796/000114036126002200/ef20063492_8k.htm) 3. 2025-12-03 Other Antitrust waiting period ends early for BioCryst's Astria deal BioCryst Pharmaceuticals announced on 2025-12-03 that the Hart-Scott-Rodino waiting period for its pending acquisition of Astria Therapeutics had been terminated early. The company's later 10-Q says the acquisition closed on 2026-01-23, with each Astria share converted into 0.59 of a BioCryst share and $8.55 in cash. [BioCryst Form 8-K (Item 8.01)](https://www.sec.gov/Archives/edgar/data/882796/000114036125044110/ef20060538_8k.htm) 4. 2025-10-14 Other BioCryst agrees to acquire Astria Therapeutics in stock and cash deal On 2025-10-14 BioCryst Pharmaceuticals, Axel Merger Sub and Astria Therapeutics signed an agreement and plan of merger. Under its terms each Astria common share would convert into 0.59 of a BioCryst share plus $8.55 in cash, subject to adjustments. BioCryst's 10-Q filed 2026-08-05 states that the merger closed on 2026-01-23 and that Astria is now a wholly owned subsidiary. [BioCryst Form 8-K (Item 1.01)](https://www.sec.gov/Archives/edgar/data/882796/000114036125038031/ef20057029_8k.htm) 5. 2025-07-25 Governance BioCryst CEO Jon Stonehouse to retire; Charlie Gayer named successor On 2025-07-25 BioCryst Pharmaceuticals CEO Jon Stonehouse told the board he would retire effective 2025-12-31. On 2025-07-27 the board appointed Charlie Gayer as president effective 2025-08-01 and as chief executive officer effective 2026-01-01. The company disclosed the changes in a Form 8-K. [BioCryst Form 8-K (Item 5.02)](https://www.sec.gov/Archives/edgar/data/882796/000117184325004869/f8k_073125.htm) 6. 2025-03-10 Litigation BioCryst sues Annora and Hetero over generic ORLADEYO filing On 2025-03-10 BioCryst Pharmaceuticals sued Annora Pharma, Hetero Labs, Hetero USA and Camber Pharmaceuticals in the U.S. District Court for the District of Delaware. The suit asserts infringement of ORLADEYO patents expiring in May 2040, after Annora filed an abbreviated new drug application and sent Paragraph IV notices in January 2025 and January 2026. BioCryst says the case is at an early stage and it cannot estimate any loss. U.S. District Court for the District of Delaware · Status: pending [BioCryst Form 10-Q (Part II, Item 1)](https://www.sec.gov/Archives/edgar/data/882796/000162828026053300/bcrx-20260630.htm) ## Pipeline | Program | Indication | Stage | |---|---|---| | Orladeyo (berotralstat) capsules and oral pellets | Hereditary angioedema prophylaxis, ages 2 and older | Marketed; pediatric pellets began shipping the week of August 3, 2026 [Source](https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/exh_991.htm) | | Navenibart | Hereditary angioedema prophylaxis (every 3 or 6 months) | Phase 3 (ALPHA-ORBIT), enrollment complete June 2026 [Source](https://www.sec.gov/Archives/edgar/data/882796/000117184326004333/exh_991.htm) | | BCX17725 (KLK5 inhibitor) | Netherton syndrome | Phase 1, part 4 dosing up to 12 patients [Source](https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/exh_991.htm) | | Rapivab (peramivir injection) | Influenza | Marketed [Source](https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/exh_991.htm) | ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BCRX on TradingView](https://www.tradingview.com/symbols/NASDAQ-BCRX/). ## SEC filings and registration - **SEC name**: Biocryst Pharmaceuticals Inc - **CIK**: 882796 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: BCRX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 4505 EMPEROR BOULEVARD, DURHAM, NC, 27703 - **Phone**: 919-859-1302 - **Shares outstanding**: 255,535,105 as of 2026-07-31 (10-Q filed 2026-08-05) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/882796/000162828026053300/bcrx-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/f8k_080526.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/882796/000117184326004333/f8k_062926.htm) filed 2026-06-29 - [8-K](https://www.sec.gov/Archives/edgar/data/882796/000117184326004096/f8k_061226.htm) filed 2026-06-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/882796/000162828026031238/bcrx-20260331.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/882796/000117184326003052/f8k_050626.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/882796/000117184326002960/f8k_050426.htm) filed 2026-05-04 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/882796/000162828026026822/bcrx-20260423.htm) filed 2026-04-23 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882796), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/biocryst-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BioCryst Pharmaceuticals (BCRX) news: lawsuit", 2026-10-31, https://aibio.space/companies/biocryst-pharmaceuticals/